Journal
MOLECULAR ONCOLOGY
Volume 3, Issue 5-6, Pages 425-438Publisher
WILEY
DOI: 10.1016/j.molonc.2009.03.004
Keywords
DNA methylation; Hypermethylation; Hypomethylation; Gene expression; Pancreatic cancer; Gemcitabine
Categories
Ask authors/readers for more resources
We performed a global methylation profiling assay on 1505 CpG sites across 807 genes to characterize DNA methylation patterns in pancreatic cancer genome. We found 289 CpG sites that were differentially methylated in normal pancreas, pancreatic tumors and cancer cell lines. We identified 23 and 35 candidate genes that are regulated by hypermethylation and hypomethylation in pancreatic cancer, respectively. We also identified candidate methylation markers that alter the expression of genes critical to gemcitabine susceptibility in pancreatic cancer. These results indicate that aberrant DNA methylation is a frequent epigenetic event in pancreatic cancer; and by using global methylation profiling assay, it is possible to identify these markers for diagnostic and therapeutic purposes in this disease. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available